Drug Trial Radar · NCT06531798
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
166
Planned (sponsor's estimate)
Start
Jan 20, 2026
Primary completion
Oct 30, 2026
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.
Conditions
- Moderate to Severe COPD
Interventions
Breztri AerosphereDrug
Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg
Primary outcomes
What the sponsor says the trial is designed to measure.
- To observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPDTime frame: 24 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Bangalore, India · Not yet recruiting
Research Site
Dalgate, Drugjan, India · Recruiting
Research Site
Hyderabad, India · Recruiting
Research Site
Lucknow, India · Recruiting
Research Site
Nagpur, India · Recruiting
Research Site
New Delhi, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.